Shanghai, China – On January 23, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") received approval from China Food and Drug Administration ("CFDA") for APOLLO Intracranial Stent System ("APOLLO") in large sizes, developed by its subsidiary MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"). The newly approved large sizes have the same indications as that of the original sizes, consisting of a stent and a delivery system for treating intracranial artery stenosis by improving blood supplies in cerebral arteries.
APOLLO was first approved by CFDA in 2004. It was China's first intracranial stent for the treatment of ischemic cerebrovascular disease. It was awarded the second prize of Shanghai Scientific Progress Award in 2009, named Shanghai Key New Product in 2010, and then listed in the National Key New Product Scheme in 2011. The newly approved product includes 12 large sizes, which further expanded APOLLO's usage in treating 4.5mm and 5.0mm cerebral vessels, meeting the unmet clinical needs.
Even since it was first available 12 years ago, the market demand of APOLLO has been increasing rapidly with a steady growth in market share. The newly approved large sizes of APOLLO will further extend its leadership position in the neuro-intervention market. MicroPort® NeuroTech will continue to innovate and devote itself in providing patients and physicians with more safe and effective products as well as total treatment solutions, building a brand that reflects our branding ideology "the Patient Always Comes First."